Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)
ID: 353382Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353382

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-190.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression," aimed at creating predictive tools and biomarkers to enhance treatment decisions for depression. This initiative consists of two phases: the UG3 phase focuses on identifying potential predictive tools through data analysis from clinical trials or pilot studies, while the UH3 phase is dedicated to validating these tools in independent clinical trials. The funding, totaling $5 million for fiscal year 2025, will support up to ten awards, with a maximum of $500,000 per year for the UG3 phase and $1.5 million for the UH3 phase. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov, with the application deadline set for October 18, 2024.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-MH-25-190-Full-Announcement.html
    RFA-MH-25-190.html
    The Department of Health and Human Services, through the National Institute of Mental Health, has released an RFP titled "Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression." This funding opportunity focuses on creating predictive tools and biomarkers to enhance treatment decisions for depression, addressing the current reliance on trial and error in treatment selection. The initiative comprises two phases: the UG3 phase, which involves preliminary studies to identify potential predictive tools through data analysis of clinical trials or pilot studies, and the UH3 phase, meant for validating these tools in independent clinical trials. The total funding allocated is $5 million for fiscal year 2025, aiming to support up to ten awards. Eligible applicants include higher education institutions, nonprofits, and governmental entities. Funding covers direct costs, with an upper limit of $500,000 per year for the UG3 phase and $1.5 million for the UH3 phase. The ultimate goal is to streamline depression treatment selection, fostering individual-level responses to established therapies by developing rigorous, validated tools for clinical use.
    Similar Opportunities
    Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Novel Assays to Address Translational Gaps in Treatment Development," aimed at developing neurophysiological assays to enhance treatment strategies for mental disorders. This initiative seeks to support partnerships among neuroscientists to optimize and evaluate pharmacodynamic measures in both human subjects and relevant animal models, thereby improving the efficiency of preclinical and clinical trials. The UG3/UH3 cooperative agreement format will facilitate a two-phase approach, focusing first on feasibility and assay optimization, followed by comparative performance evaluations. Interested applicants can find more information and submit proposals by June 20, 2025, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Novel Assays to Address Translational Gaps in Treatment Development" initiative, aimed at advancing neurophysiological measures that can serve as assays for drug and device therapies in mental health research. This funding opportunity encourages collaborative partnerships among neuroscientists to optimize in vivo testing in both preclinical species and humans, with a focus on bridging the gap between preclinical and clinical measures to enhance therapeutic outcomes for mental disorders. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with key deadlines including an application due date of January 21, 2025, and a funding expiration on June 21, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the National Cooperative Drug/Device Discovery/Development Groups (NCDDG) funding opportunity, aimed at advancing innovative therapies for mental disorders through cooperative agreements. This initiative encourages applications focused on the discovery, preclinical development, and proof of concept testing of new pharmacological agents and neuromodulatory devices, with a strong emphasis on partnerships between academia and industry. The program is designed to facilitate the transition of drug and device solutions from discovery to early human trials, addressing critical mental health challenges. Interested applicants must comply with NIH registration and submission requirements, with application deadlines beginning on January 25, 2025, and funding awards potentially lasting up to five years. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-352.html.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at advancing the development of innovative brain stimulation devices for mental health disorders. This initiative seeks applications that either create novel brain stimulation technologies or significantly enhance existing FDA-approved devices through improvements in hardware and software, focusing on increased spatiotemporal precision and multi-focal, closed-loop approaches. The program is particularly important for addressing limitations in current mental health treatments and fostering technological innovation in this field. Interested applicants can apply for grants up to $275,000 for a two-year project period, with applications due by January 7, 2028. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-286.html.
    Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is inviting applications for the funding opportunity titled "Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes" (PAR-25-206). This initiative aims to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions, focusing on aspects such as feasibility, tolerability, acceptability, safety, and potential effectiveness. The program is crucial for advancing mental health treatment and understanding, particularly for underserved populations, by gathering data that will inform larger-scale effectiveness trials. Interested applicants can apply for grants of up to $750,000 over a three-year period, with the submission window opening on January 5, 2025, and closing on January 7, 2028. For more information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-206.html.
    Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)." This grant aims to support innovative research utilizing invasive neural recording methods to explore the neural circuitry associated with mental health disorders, focusing on high-risk applications that address significant gaps in knowledge regarding complex moods and cognitive behaviors. The initiative seeks to bridge basic neuroscience with applied mental health interventions, encouraging diverse research teams to utilize advanced methodologies. The estimated funding amount is capped at $200,000, with applications due by January 7, 2028. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-291.html.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)" aimed at advancing the development of innovative brain stimulation devices for mental health treatment. This initiative seeks applications that either create novel devices or significantly enhance existing FDA-approved devices through hardware and software improvements, focusing on increased precision and effectiveness in treatment. The funding underscores the importance of multidisciplinary collaboration in neuroscience and engineering, with an emphasis on innovative approaches rather than incremental changes. Interested applicants can find more information and submit proposals by January 7, 2028, with no budget cap but a maximum project duration of five years. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-287.html.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)." This initiative aims to support invasive neural recording studies that investigate the neural circuitry and dynamics associated with mental health disorders, encouraging researchers to address specific questions with high translational potential. The program emphasizes the importance of innovative collaborations in neuroscience and engineering to enhance understanding and therapeutic approaches for mental health challenges. Applications will open on January 5, 2025, with a project duration of up to five years and no budget limits. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-290.html.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)." This initiative aims to advance the discovery and development of innovative drug and device therapies targeting mental disorders and alcohol use disorder (AUD) through collaborative efforts among academia, biotechnology, and pharmaceutical sectors. The program emphasizes multidisciplinary approaches and partnerships to facilitate early-phase human trials, develop pharmacologic and neuromodulatory tools, and validate experimental therapeutic studies. Eligible applicants include a wide range of organizations, such as educational institutions and nonprofits, with no cap on application budgets, although realistic estimates are expected. The total project period cannot exceed five years, and applications must adhere to NIH guidelines. Interested parties can find more information and submit inquiries via email to OERWebmaster03@od.nih.gov, with the application deadline set for February 24, 2025.